Heart Failure — Cardiac Contractility Modulation in Chagas Heart Disease
Citation(s)
Abi-Samra F, Gutterman D Cardiac contractility modulation: a novel approach for the treatment of heart failure. Heart Fail Rev. 2016 Nov;21(6):645-660. Review.
Barretto AC, Ianni BM The undetermined form of Chagas' heart disease: concept and forensic implications. Sao Paulo Med J. 1995 Mar-Apr;113(2):797-801. Review.
Bestetti R Stroke in a hospital-derived cohort of patients with chronic Chagas' disease. Acta Cardiol. 2000 Feb;55(1):33-8.
de Paola AA, Gomes JA, Terzian AB, Miyamoto MH, Martinez Fo EE Ventricular tachycardia during exercise testing as a predictor of sudden death in patients with chronic chagasic cardiomyopathy and ventricular arrhythmias. Br Heart J. 1995 Sep;74(3):293-5.
Dias JC, Kloetzel K The prognostic value of the electrocardiographic features of chronic Chagas' disease. Rev Inst Med Trop Sao Paulo. 1968 May-Jun;10(3):158-62.
Dias JC, Prata A, Correia D Problems and perspectives for Chagas disease control: in search of a realistic analysis. Rev Soc Bras Med Trop. 2008 Mar-Apr;41(2):193-6. Review.
Dias JC The indeterminate form of human chronic Chagas' disease A clinical epidemiological review. Rev Soc Bras Med Trop. 1989 Jul-Sep;22(3):147-56. Review.
Moncayo A, Silveira AC Current epidemiological trends for Chagas disease in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009 Jul;104 Suppl 1:17-30.
Oliveira JS, Barbieri Neto J [Chagasic cardiopathy. Rupture of the apical aneurysm]. Arq Bras Cardiol. 1970 Oct;23(5):335-8. Portuguese.
Pinto Dias JC [Natural history of Chagas disease]. Arq Bras Cardiol. 1995 Oct;65(4):359-66. Review. Portuguese.
Rassi A Jr, Dias JC, Marin-Neto JA, Rassi A Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease. Heart. 2009 Apr;95(7):524-34. doi: 10.1136/hrt.2008.159624. Epub 2009 Jan 8.
Rassi A Jr, Rassi SG, Rassi A Sudden death in Chagas' disease. Arq Bras Cardiol. 2001 Jan;76(1):75-96. Review. English, Portuguese.
Schmunis GA Epidemiology of Chagas disease in non-endemic countries: the role of international migration. Mem Inst Oswaldo Cruz. 2007 Oct 30;102 Suppl 1:75-85. Erratum in: Mem Inst Oswaldo Cruz. 2007 Dec;102(8):2 p following 1009.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
